Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
10 evidence topics · 9 sources
Patient-reported outcome measures at every visit
“Patients should be assessed for disease activity, impact, and control at all visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The UAS7, calculated as the sum of daily scores over 7 consecutive days, should be routinely used to monitor disease activity and treatment response in patients with CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to highlight that patients need good counseling regarding continuous treatment and using PROMs, especially about using the UAS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Stepping treatment up or down: assess, act and adjust, and reassess
“Treatment should follow the basic principles of treating as much as needed and as little as possible, taking into consideration that the activity of the disease may vary” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This implies stepping up or stepping down in the treatment algorithm according to the course of disease following the principle assess, act & adjust, and reassess” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In order to constantly ensure the right level of treatment, patients need to be seen at regular intervals and adjustments are recommended based on the level of symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For a stepdown, different options exist but costs are especially relevant for choosing which step to take first.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients who are in the range of UCT 12–15, therefore a step up might also be required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab interval prolongation after 3 months of complete control
“After 3 months of complete control, the interval can be prolonged until long as first wheals reappear, as there is no tachyphylaxis nor have relevant levels of blocking antibodies been described.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“But also, the prolongation of the interval is strictly off label.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab step-down: relapse after gradual de-escalation versus abrupt discontinuation, meta-analysis
“Random-effects proportion meta-analysis (DerSimonian-Laird logit transformation) determined pooled relapse rates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall pooled post-discontinuation relapse rate was 39.5% (95% CI: 30.1%-49.7%; I2 = 91.5%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Gradual de-escalation achieved a significantly lower pooled relapse rate compared with abrupt discontinuation (31.2% [95% CI: 20.3%-44.7%] vs. 48.9% [95% CI: 37.0%-61.0%], Qb = 8.12, df = 1, p = 0.004).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Concomitant angioedema was an independent risk factor for relapse (multivariate OR = 2.399, p = 0.004), whereas gradual de-escalation was protective (multivariate OR = 0.373, p = 0.005).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab cessation: pooled relapse across 41 stopping risk sets and uncertainty about stopping strategies
“Forty-one stopping risk sets (2,643 patients; 1,209 source-reported events) yielded a pooled proportion of 46.6% (95% CI 40.1-53.2%; I2 = 87.7%; prediction interval 16.0-79.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Relapse is common after cessation, but high heterogeneity limits individualized prediction. The evidence cannot establish a causal advantage of any stopping strategy or an immune endotype for recurrence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary care: periodic antihistamine withdrawal to test for remission
“Urticaria is a common condition presenting both as acute and chronic disease within primary care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, when remission is achieved, therapy should be withdrawn every 3–6 months to discover whether natural remission has occurred.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Barzolvolimab phase 3b extension: observation of controlled disease and retreatment on flare
Treatment escalation in practice: CURE registry
“This data analysis from the Chronic Urticaria Registry (CURE) aimed to describe treatment patterns and identify unmet needs in real-world practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“About one-third (28.6%) of patients clinically eligible for escalation at BL (UCT < 12) did not receive step-up treatment (18.0%) or were even stepped down (10.6%) and remained poorly controlled at FU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many patients with poorly controlled CSU do not receive guideline-recommended treatment escalation and remain symptomatic on their current treatments, which deserves further attention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mobile app symptom monitoring: adherence to CRUSE
“We analysed data from 2085 patients (66,114 days). Median adherence to the CRUSE app was of 22 days (24.4% of 90 days).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our findings suggest that age, male sex, residence in Europe, and the use of monoclonal antibodies are significant factors associated with increased adherence to the CRUSE app.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality-improvement study of guideline-based care: planned steps
“Finally, some physicians are not aware of, or do not adhere to, international guidelines available for the treatment of CSU” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Step 3 (quality improvement): Recommendations to improve quality of care for patients with CSU will be developed, pilot tested, and published.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote